RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $87 from $82 and keeps an Outperform rating on the shares ahead of the company’s “highly anticipated” launch of aficamten in 2026. The firm is updating its modeling assumptions on opex and revenues to better reflect what early U.S. launch dynamics in 2026 could look like following the December 2025 PDUFA, anchoring to historical competitor data, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $90 from $80 at B. Riley
- Cytokinetics presents additional data from MAPLE-HCM
- Promising Potential of Cytokinetics’ Aficamten Drives Buy Rating Amid Anticipated U.S. Approval
- Private Markets: Anthropic projects $70B in revenue in 2028
- Cytokinetics (CYTK) Faces Class Action Over Misleading Aficamten Claims